Literature DB >> 31373406

Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma.

Chuanjie Zhang1, Zongtai Li2, Jiateng Hu3, Feng Qi4, Xiao Li5, Jun Luo6.   

Abstract

Nowadays, an increasing number of studies illustrated that bladder urothelial cancer (BLCA) may act as the most common subtype of urological malignancies with a high rate of recurrence and metastasis. In this study, we attempted to establish a prognostic model and identify the possible pathway crosstalk. Long noncoding RNAs (lncRNAs) and mRNA expression and corresponding clinical information of patients with BLCA were downloaded from The Cancer Genome Atlas (TCGA). The differentially expressed genes analysis, univariate Cox analysis, the least absolute shrinkage, and selection operator Cox (LASSO Cox) regression model were then applied to identify five crucial lncRNAs (AC092725.1, AC104071.1, AL023584.1, AL132642.1, and AL137804.1). The multivariate cox analysis was utilized to calculate the regression coefficients (βi ). The risk-score model was subsequently constructed as follows: (0.13541AC092725.1) + (0.20968AC104071.1) + (0.1525AL023584.1) - (0.14768AL132642.1) + (0.14387AL137804.1). Nomogram and assessment of overall survival (OS) prediction were verificated by the receiver operating characteristic curve in the testing group. As to 3-, 5-year OS prediction, the area under curve (AUC) for the nomogram of training data set was 0.83 and 0.86. Besides, the AUC (0.883 and 0.879) presented excellent predictive power in the testing group. In addition, the calibration plots validated the predictive performance of the nomogram. Weighted correlation network analysis (WGCNA) coupled with functional enrichment analysis contributed to explore the potential pathways, including PI3K-Akt, HIF-1, and Jak-STAT signaling pathways. Construction of the risk-score model and data analysis were both derived from multiple packages on the basis of the R platform chiefly.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  The Cancer Genome Atlas; bladder urothelial cancer; long noncoding RNAs; prognostic biomarkers; risk-score model

Mesh:

Substances:

Year:  2019        PMID: 31373406     DOI: 10.1002/jcb.29330

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature.

Authors:  Jianguo Lai; Bo Chen; Guochun Zhang; Xuerui Li; Hsiaopei Mok; Ning Liao
Journal:  J Transl Med       Date:  2020-11-07       Impact factor: 5.531

2.  Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.

Authors:  Yucai Wu; Lei Zhang; Shiming He; Bao Guan; Anbang He; Kunlin Yang; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

3.  Recognition of Glycometabolism-Associated lncRNAs as Prognosis Markers for Bladder Cancer by an Innovative Prediction Model.

Authors:  Dongdong Tang; Yangyang Li; Ying Tang; Haoxiang Zheng; Weihan Luo; Yuqing Li; Yingrui Li; Zhiping Wang; Song Wu
Journal:  Front Genet       Date:  2022-07-19       Impact factor: 4.772

4.  A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer.

Authors:  Yifan Wang; Lutao Du; Xuemei Yang; Juan Li; Peilong Li; Yinghui Zhao; Weili Duan; Yingjie Chen; Yunshan Wang; Haiting Mao; Chuanxin Wang
Journal:  Aging (Albany NY)       Date:  2020-02-12       Impact factor: 5.682

5.  Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.

Authors:  Huaide Qiu; Xiaorong Hu; Chuan He; Binbin Yu; Yongqiang Li; Jianan Li
Journal:  Front Genet       Date:  2020-02-05       Impact factor: 4.599

6.  LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis.

Authors:  Huifeng Bi; Zhenhua Shang; Chunsong Jia; Jiangtao Wu; Bo Cui; Qi Wang; Tongwen Ou
Journal:  Onco Targets Ther       Date:  2020-11-04       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.